Cedarburg Hauser Pharmaceuticals

Cedarburg Hauser Pharmaceuticals

Experienced contract development and manufacturing organization (cdmo) for active pharmaceutical. Learn more
  • Edit
DateInvestorsAmountRound

$7.0m

Series A

$41.0m

Valuation: $41.0m

Acquisition
Total FundingCAD9.5m

Recent News about Cedarburg Hauser Pharmaceuticals

Edit
More about Cedarburg Hauser Pharmaceuticalsinfo icon
Edit

Cedarburg Hauser Pharmaceuticals, a subsidiary of Albany Molecular Research Inc. (AMRI), specializes in providing comprehensive drug development and manufacturing services to pharmaceutical companies. Operating in the pharmaceutical and biotechnology sectors, the company offers a range of services including API (Active Pharmaceutical Ingredient) development, drug product manufacturing, and analytical testing. Cedarburg Hauser Pharmaceuticals serves clients ranging from small biotech firms to large pharmaceutical companies, helping them navigate the complex journey from drug discovery to market. The business model is service-based, generating revenue through contracts for drug development, manufacturing, and testing services. By leveraging its integrated approach and industry-leading expertise, Cedarburg Hauser Pharmaceuticals ensures high-quality and efficient drug development processes for its clients.

Keywords: drug development, API manufacturing, pharmaceutical services, biotechnology, analytical testing, drug discovery, contract manufacturing, pharmaceutical clients, integrated services, high-quality production.